Gamma-Glutamyl Transpeptidase to Neutrophil Ratio as Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection
Xueqin Shen,Xiaoping Niu
DOI: https://doi.org/10.2147/jhc.s478186
2024-10-27
Journal of Hepatocellular Carcinoma
Abstract:Xueqin Shen, 1, 2 Xiaoping Niu 2 1 Department of Clinical Nutrition, Yijishan Hospital of Wannan Medical College, Wuhu, People's Republic of China; 2 Department of Gastroenterology, Yijishan Hospital of Wannan Medical College, Wuhu, People's Republic of China Correspondence: Xiaoping Niu, Department of Gastroenterology, Yijishan Hospital of Wannan Medical College, No. 2 Zheshan West Road, Wuhu, Anhui, 241000, People's Republic of China, Email Background: The close association between inflammation and the clinical outcomes of hepatocellular carcinoma (HCC) has been extensively documented. This study aims to analyze the association between a novel inflammatory indicator, the gamma-glutamyl transpeptidase to neutrophil ratio (GNR), and HCC prognosis following curative resection. Methods: A cohort of 204 eligible HCC cases were included. Based on an optimal cut-off value determined utilizing the X-tile software, patients were categorized into low- and high-GNR groups. The overall survival (OS) and recurrence-free survival (RFS) rates were assessed using the Kaplan-Meier analysis method with Log rank tests. Multivariate Cox proportional hazard regression was used to investigate the independent association between GNR and HCC prognosis. Restricted cubic splines were used to explore the nonlinear relationship between GNR and the risk of death or recurrence. Results: The low GNR group exhibited significantly higher 3-year OS and RFS rates than the high GNR group. Multivariate Cox analysis indicated that a high GNR level was independently associated with poor OS and RFS. A linear correlation between GNR and the risk of death, as well as a nonlinear inverted "U" shape correlation between GNR and the risk of recurrence, were observed. Conclusion: The findings provide evidence supporting the independent association of GNR with HCC prognosis. These results offer promise for enhancing prognosis assessments and guiding active monitoring strategies for patients with HCC post-curative resection. Keywords: hepatocellular carcinoma, gamma-glutamyl transpeptidase to neutrophil ratio, prognosis, curative resection Primary liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide in 2022, with an estimated 865,000 new cases and 758,000 deaths. 1 Hepatocellular carcinoma (HCC) accounts for 75–85% of all cases and is the predominant type. 1 Despite curative resection being the primary treatment for HCC, post-surgical outcomes are often unsatisfactory. 2,3 Thus, there is a crucial need to identify high-risk patients with a poor prognosis in a practical and simple manner to enhance clinical management and prognosis. The close association between inflammation and the clinical outcomes of HCC is well-documented. 4 Gamma-glutamyl transpeptidase (GGT), a serum enzyme and liver function marker, is linked to inflammation and carcinogenesis. 5 Previous studies have demonstrated that preoperative serum GGT levels are independently associated with the prognosis of HCC after liver transplantation, after transcatheter arterial chemoembolization, after ablation therapy, after curative resection, or in HCC cases of AFP-negative. 6–10 Neutrophils (NEUT), a component of the inflammatory response, have been linked to aggressive behavior in HCC patients. 11 Neutrophils not only influence the development of HCC but also play a crucial role in predicting clinical outcomes. 12 However, no studies have examined the relationship between the preoperative gamma-glutamyl transpeptidase to neutrophil ratio (GNR) and HCC prognosis following curative resection. This study aimed to address this gap in the literature. We retrospectively enrolled 204 eligible patients diagnosed with primary HCC between March 2012 and January 2021 at Yijishan Hospital of Wannan Medical College. Patients were excluded based on the following criteria: (1) previous hepatectomy; (2) multiple primary malignancies; (3) distant organ metastasis; (4) neoadjuvant therapy; (5) diseases that affect hematological parameters, such as: acute inflammatory disease, autoimmune disease, or haematopoietic system disease; (6) survival time < 1 month; (7) incomplete clinical data or follow-up information. Patients were staged using the American Joint Committee on Cancer (AJCC) 8th staging system. 13 Postoperative follow-up occurred every 3–6 months in the first 2 years and then every 6–12 months. Patients underwent imaging examinations, such as ultrasound, computed tomography, or magnetic resonance imaging, for a comprehensive evaluation during the follow-up period. Prognostic information was obtained via medical records a -Abstract Truncated-
oncology